Rotarix^™: an example of a recently developed oral vaccine against rotavirus for infants

References

• Linhares AC, Ortega E, Costa Clemens SA, et al. Rotavirus gastroenteritis in Latin America: a hospital-based study in children under three years of age. PAHO, in press.
   Google Scholar
• Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis 2006; 12:304–306.
   Google Scholar
• Cunliffe NA, Kilgore PE, Bresee JS, et al. Epidemiology of rotavirus diarrhoea in Africa: a review to assess the need for rotavirus immunization. Bull Wrld Hlth Org 1998; 76:525–537.
   Google Scholar
• Molbak K, Fischer TK, Mikkelsen CS. The estimation of mortality due to rotavirus infections in sub-Saharan Africa. Vaccine 2000; 19: 393–395.
   Google Scholar
• International Centre for Diarrhoeal Disease Research, Bangladesh. Centre for Health and population research. Estimated deaths due to rotavirus in Bangladesh. Health SciBul12006; 4: 6–10.
   Google Scholar
• Jain V, Parashar UD, Glass RI, Bhan MK. Epidemiology of rotavirus in India. Indian J Pediatr 2001; 68: 855–862.
   Google Scholar
• Vesikari T. Trials of oral bovine and rhesus rotavirus vaccines in Finland: a historical account and present status. Arch Virol Suppl 1996; 12: 177–186.
   Google Scholar
• Clark HF, Furukawa T, Bell LM, et al. Immune response of infants and children to low-passage bovine rotavirus (strain WC3). Am J Dis Child 1986; 140:350–356.
   Google Scholar
• Kapikian AZ, Hoshino Y, Chanock RM, Perez-Schael I. Jermerian and modified Jermerian approach to vaccination against rotavirus diarrhea using a quadrivalent rhesus rotavirus (RRV) and human-RRV reassortant vaccine. Arch Virol Supp11996; 12: 163–175.
   Google Scholar
• Withdrawal of rotavirus vaccine recommendation. MMWR 1999; 48: 1007.
   Google Scholar
• Bernstein DI, Sander DS, Smith VE, Schiff GM, Ward RL. Protection from rotavirus reinfection: 2-year prospective study. J Infect Dis 1991; 164:277–283.
   Google Scholar
• Bernstein DI, Smith VE, Sherwood JR, et al. Safety and immunogenicity of live, attenuated human rotavirus vaccine 89-12. Vaccine 1998; 16:381–387.
   Google Scholar
• Bernstein DI, Sack DA, Rothstein E, et al. Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial. Lancet 1999; 354:287–290.
   Google Scholar
• Bernstein DI, Sack DA, Reisinger K, Rothstein E, Ward RL. Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants. J Infect Dis 2002; 186: 1487–1489.
   Google Scholar
• Vesikari T, Karvonen A, Korhonen T, et al. Safety and immunogenicity of RIX4414 live attenuated human rotavirus vaccine in adults, toddlers and previously uninfected infants. Vaccine 2004; 22:2386–2842.
   Google Scholar
• Vesikari T, Karvonen A, Puustinen L, et al. Efficacy of RIX 4414 live attenuated human rotavirus vaccine in Finnish infants. Pediatt Inf Dis J2004; 23:937–943.
   Google Scholar
• Salinas B, Perez Schael I, Linhares AC, et al. Evaluation of safety, immunogenicity and efficacy of an attenuated rotavirus vaccine, RIX4414: A randomized, placebo-controlled trial in Latin American infants. Pediatr Infect Dis J2005; 24:807–816.
   Google Scholar
• Dennehy PH, Brady RC, Halperin SA, et al. Comparative evaluation of safety and immunogenicity of two dosages of an oral live attenuated human rotavirus vaccine. Pediatr InfDis J2005; 24:481–488.
   Google Scholar
• Phua KB, Quak SL, Lee BW, et al. Evaluation of RIX 4414 live attenuated human rotavirus vaccine in a randomised, double-blind, placebo-controlled Phase II trial involving 2464 Singaporean infants. J Infect Dis 2005; 192: S6–S16.
   Google Scholar
• Steele AD, De Vos B, Tumbo J, et al. A co-administration study in South African infants of a new live-attenuated oral rotavirus vaccine (RIX4414) and poliovirus vaccines. Vaccine, submitted.
   Google Scholar
• Steele AD, Tumbo J, Reynders J, et al. Comparison of 2 different regimens (two doses versus three doses) in terms of reactogenicity and immunogenicity of the live attenuated human rotavirus vaccine RotarixTM (RIX4414) in South African infants. Presented at the 11th Asian Conference on Diarrhoeal Diseases and Nutrition ASCODD, Abstract AA107, 8–10 March 2006, Bangkok, Thailand.
   Google Scholar
• Zaman K, Sack DA, Yunus M, et al. Immunogenicity and reactogenicity of a human rotavirus vaccine in Bangladeshi children. Presented at the 12th Asia Pacific Congress of Paediatrics (APCP), Sri Lanka, 12–15 March 2007.
   Google Scholar
• Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Eng1J Med 2006; 354: 11–22.
   Google Scholar
• 24. Vesikari T, Prymula R, Schuster V, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with diphtheria-tetanus-pertussis (DTPa)-combined vaccines in healthy infants from Europe. Presented at the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID. Basel, Switzerland, May 3–5,2006.
   Google Scholar
• 25.Tejedor JC, Diez-Delgado J, Aristegui J, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Neisseria meningitidis serogroup C vaccine (MeningitecTm) in healthy infants from Spain. Presented at the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID. Basel, Switzerland, May 3–5, 2006.
   Google Scholar
• 26.Schuster V, Otto W, Cohen R, et al. Rotarix (RIX4414), an oral human rotavirus vaccine, is highly immunogenic when co-administered with a Streptococcus pneumoniae conjugate vaccine (PrevenarTM) in healthy infants from France and Germany. Presented at the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID. Basel, Switzerland, May 3–5,2006.
   Google Scholar
• 27.Velazquez FR, Abate H, Bouckenooghe A, et al. RIX4414, the human G1P8 rotavirus vaccine is highly efficacious during the second year of life. Presented at the 46th Annual Interscience Conference on antimicrobial agents and chemotherapy. San Francisco, CA, USA, September 27–30, 2006.
   Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. Human rotavirus vaccine Rotarix TM (RIX4414) is highly efficacious in Europe. Presented at the 24th Annual Meeting of the European Society for Pediatric Infectious Diseases ESPID. Basel, Switzerland, May3-5, 2006.
   Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. Human rotavirus vaccine Rotarix TM is highly efficacious in Europe during the first two years of life. Presented at the 25th Meeting of the European Society for Paediatric Infectious Diseases. Porto, May 2–4, 2007.
   Google Scholar
• Vesikari T, Karvonen A, Prymula R, et al. RIX4414 is highly effective against severe RVGE caused by specific rotavirus types during the first two years of life. Presented at IDSA, San Diego, USA, October 4–7, 2007.
   Google Scholar
• Vesikari T, Prymula R, Schuster V, et al. Early protection against rotavirus RotarixTM (RIX4414) experience in a European setting. Presented at ICID, Lisbon, Portugal, June 15–18,2006.
   Google Scholar